Dermatoscope Market Worth $2.0 Billion By 2030 | CAGR: 12.1%

 

The global Dermatoscope Market size is expected to reach USD 2.0 billion by 2030, according to a new report by Grand View Research, Inc., registering a CAGR of 12.1% during the forecast period. Dermatoscopy plays a vital role in screening for skin cancer, which has resulted in the early detection and identification of pigmented lesions. Benign pigmented moles possess a certain risk of developing melanoma.

The incidence of several skin conditions has increased during the COVID-19 pandemic. Contact dermatitis, pressure urticaria, pressure injury, itching, seborrheic dermatitis, acne, and worsening of pre-existing skin diseases. The Dermatology Practical & Conceptual conducted a survey on 678 dermatologists to investigate the impact of the coronavirus disease 2019 outbreak on the daily practice of dermatologists working with skin cancer patients. This survey stated that there was a 75% reduction in daily work activity and 118 dermatologists experienced telemedicine for the first time. However, with the ease in the restrictions, the aesthetic industry is again witnessing lucrative growth rate.

Skin cancer is a chronic disease affecting a large population of the world. The rising incidence of melanoma and nonmelanoma skin cancers is providing an upthrust to the market. Certain moles, such as giant congenital pigmented hairy moles, are at high risk of developing melanoma. This has boosted the need for effective diagnosis with dermatoscopes.

Early detection of skin cancer has been proven to be very useful in its effective treatment. Hence, a rising number of awareness campaigns is estimated to fuel the demand for dermatoscopes, which is anticipated to propel the market. Earlier, the usage of these technologically advanced devices was limited to the detection of noninvasive melanoma. However, with technological advancements, their application has widened to the advanced diagnosis of various skin disorders.

North America region is currently the dominant region in terms of market share in dermatoscopes market. High prevalence of skin diseases, the presence of advanced healthcare infrastructure, presence of medical device manufacturers, and huge economic development are some of the major factors propels the North America dermatoscopes market.

Related Press Release@ Dermatoscope Market Report

Dermatoscope Market Report Highlights

• Contact dermatoscopes dominated the market in 2022 owing to abundant availability of these products
• Hybrid dermatoscopes are anticipated to exhibit lucrative CAGR over the forecast period owing to unique features of contact as well as noncontact dermatoscopes
• In 2022, LED technology held the largest market share owing to benefits associated with its usage, which include exact light intensity, color, and, homogeneity rendering precise diagnosis
• Handheld devices generated maximum revenue share in 2022 due to the fact that they are relatively compact and consist of rechargeable batteries that enable easy manoeuvring across the body
• Amongst end use segments, dermatology clinics dominated the market in 2022 and is also expected to exhibit attractive growth over the forecast period
• The availability of sophisticated and technologically advanced medical equipment at dermatology clinics provides patients quick and rapid diagnosis, which helps deliver better treatment
• North America held largest market share in 2022 owing to increase in the prevalence of skin cancer and growth in the adoption of advanced diagnostic technologies in this region
• Asia Pacific is anticipated to exhibit attractive growth over the forecast period due to the introduction of novel technologies in countries such as Japan and China

Dermatascope Market Segmentation

Grand View Research has segmented the global dermatascope market based on product, technology, modality, end-use, and region:

Dermatoscope Product Outlook (Revenue, USD Million, 2018 - 2030)

• Contact Dermatoscope
• Hybrid Dermatoscope
• Noncontact Dermatoscope

Dermatoscope Technology Outlook (Revenue, USD Million, 2018 - 2030)

• LED
• Xenon
• Halogen
• Ultraviolet

Dermatoscope Modality Outlook (Revenue, USD Million, 2018 - 2030)

• Handheld
• Trolley Mounted
• Headband

Dermatoscope End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Dermatology Clinics
• Hospitals

Dermatoscope Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America
• U.S.
• Canada
• Europe
• Germany
• U.K.
• France
• Italy
• Spain
• Denmark
• Sweden
• Norway
• Asia Pacific
• Japan
• China
• India
• Australia
• South Korea
• Thailand
• Latin America
• Brazil
• Mexico
• Argentina
• MEA
• South Africa
• Saudi Arabia
• UAE
• Kuwait

List of Key Players of Dermatoscope Market

• Canfield Scientific, Inc.
• 3Gen
• FotoFinder Systems
• Optilia Instruments AB
• HEINE Optotechnik GmbH & Co. KG
• Caliber Imaging & Diagnostics, Inc.
• Firefly Global
• ILLUCO Corporation Ltd.
• Welch Allyn
• Bio-Therapeutic Inc.

About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com

Urinary Tract Infection Testing Market To Reach $812.01 Million By 2030

 

The global Urinary Tract Infection Testing Market is expected to reach USD 812.01 million by 2030, according to a new report by Grand View Research, Inc. The market is anticipated to grow at a CAGR of 4.4% from 2023 to 2030. The urinary tract infection (UTI) testing market is witnessing growth due to factors such as rising disease burden, increasing geriatric population, rapid technological advancements, and high R&D investments by key players to introduce novel & innovative products, such as self-testing & rapid Point-of-Care (PoC) devices products.

Urinary tract infection is becoming a common global concern. According to research studies, UTI occurs in one in five adult women at some point in their life. In the U.S., about 25%-40% of women aged 20-40 have suffered a UTI. In the U.S., about 250,000 cases of pyelonephritis are reported every year. In women aged 18-19, its incidence is about 28/10,000, out of which 7% of cases require hospital admission. Genetic and cultural factors may influence its prevalence; for instance, in South Korea, the incidence of pyelonephritis is around 59/10,000. Its recurrence is more common than other UTIs, with the recurrence rate being 5.7% in men and 9% in women.

Patients with diabetes are at increased risk of developing urinary tract infections such as acute cystitis, and therefore, the increasing global prevalence of diabetes is likely to contribute to cystitis growth. According to an NCBI article, type 2 diabetes raises UTI risk and patients with type 2 diabetes experience frequent & severe UTIs. According to the International Diabetes Federation (IDF) data from 2021, approximately 643 million individuals will have diabetes by 2030 and 783 million by 2045. Moreover, the estimated prevalence of asymptomatic bacteriuria in diabetic females is 26%, compared to 6% in nondiabetic females. Such factors are expected to boost the prevalence of cystitis globally.

However, due to the rise in awareness about such diseases, the demand for specialist treatment has increased in recent years. According to the U.S. Department of Health and Human Services, in the U.S., the number of practicing urologists in 2020 was 4.07 per 100,000 populations. The report further stated that due to the rise in demand, a shortage of urologists was observed, which is likely to exceed nearly 3,600 physicians by 2025. This can impede market growth in the coming years. Moreover, COVID-19 has had a detrimental impact on the industry. Individuals with UTIs have experienced substantial disruptions in testing and emergency care.

Key players are introducing novel products to strengthen their portfolios. For instance, in September 2021, OpGen, Inc. announced initiating clinical trials of the Unyvero Urinary Tract Infection Panel. The panel can analyze a broad range of pathogens and antimicrobial resistance markers directly from a urine sample. Successful clinical trials and the launch of such technologically advanced & efficient products are anticipated to drive market growth over the coming years. Similarly, in July 2020, Uqora, Inc. (Pharmavite, LLC), a urinary health biotechnology company, launched a UTI diagnostic and management kit. The kit includes a rapid UTI diagnostic device, Clarify, compatible with a PoC and homecare setting.

List of Key Players of Urinary Tract Infection Testing Market

• QIAGEN
• Accelerate Diagnostics, Inc.
• Bio-Rad Laboratories, Inc.
• F. Hoffmann-La Roche Ltd.
• Danaher Corporation
• Siemens Healthcare GmbH
• Randox Laboratories Ltd.
• Thermo Fisher Scientific, Inc.
• bioMérieux SA
• T2 Biosystems, Inc.

Related Press Release@ Urinary Tract Infection Testing Market Report

Urinary Tract Infection Testing Market Highlights

• Cystitis dominated the market in 2022, with an estimated market share of 41.42%. This can be attributed to the high incidence & recurrence rate of cystitis, increased number of product approvals, and the high number of diabetes patients who are more prone to cystitis
• The reference laboratories segment held a share of 26.66% in 2022 attributed to the ongoing efforts of reference laboratories to enhance patient outcomes by offering diagnostic facilities at retail level.
• North America dominated the overall urinary tract infection market in terms of value. This can be attributed to better reimbursement facilities and a rise in the adoption of novel diagnostic products due to increased awareness

Urinary Tract Infection Testing Market Segmentation

Grand View Research has segmented the global urinary tract infection testing market on the basis of type, end-use, and region:

Urinary Tract Infection Testing Type Outlook (Revenue, USD Million, 2018 - 2030)

• Urethritis
• Cystitis
• Pyelonephritis
• Vaginitis

Urinary Tract Infection Testing End-use Outlook (Revenue, USD Million; Volume, Units, 2018 - 2030)

• General practitioners (GP's)
• Urologists
• Urogynecologists
• Accountable Care Organization (ACO's)
• Hospital Laboratories
• Reference Laboratories
• Hospital Emergency Departments
• Urgent Care

Urinary Tract Infection Testing Regional Outlook (Revenue, USD Million, Volume, Units, 2018 - 2030)

• North America
• U.S.
• Canada
• Europe
• Germany
• UK
• France
• Italy
• Spain
• Denmark
• Sweden
• Norway
• Asia Pacific
• Japan
• China
• India
• Australia
• South Korea
• Thailand
• Latin America
• Brazil
• Mexico
• Argentina
• Middle East and Africa (MEA)
• South Africa
• Saudi Arabia
• UAE
• Kuwait

About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com